NGM

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on NGM Biopharmaceuticals (NGM – Research Report) today and set a price target of $35.00. The company's shares closed last Wednesday at $10.58, close to its 52-week low of $10.49. According to TipRanks.com, Mamtani has 0 stars on 0-5 stars ranking scale with an average return of -33.2% and a 19.4% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Spectrum Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for NGM Biopharmaceuticals with a $35.00 average price target.
https://www.tipranks.com/news/blurbs/ngm-biopharmaceuticals-ngm-receives-a-buy-from-b-riley-financial-2?utm_source=advfn.com&utm_medium=referral